ALLMedicine™ Breast Cancer Chemotherapy Center

Feb 11th, 2021 - Left-ventricular (LV) strain measurements with the Displacement Encoding with Stimulated Echoes (DENSE) MRI sequence provide accurate estimates of cardiotoxicity damage related to breast cancer chemotherapy. This study investigated an automated LV...

Jan 8th, 2021 - Different tumor-related factors have been proposed to assess the risk of disease progression and death in women undergoing neoadjuvant breast cancer chemotherapy. Recently, besides the classical pre-treatment clinical stage (CS) and post-treatment...

Aug 25th, 2020 - Multidrug resistance (MDR) limits the beneficial outcomes of conventional breast cancer chemotherapy. Ras-related nuclear protein (Ran-GTP) plays a key role in these resistance mechanisms, assisting cancer cells to repair damage to DNA. Herein, we...

Aug 4th, 2020 - Progress in oncology has allowed to improve outcomes in many breast cancer patients. The core stone of breast cancer chemotherapy is anthracycline-based chemotherapy. Unfortunately, anthracyclines cause cardiotoxicity which is a limiting factor of...

Jul 19th, 2020 - Our study aimed to analyze the risk of hematologic malignancies (HM) associated with the use of G-CSF with chemotherapy for BC. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident breast ca...

Jan 22nd, 2019 - New research in the January 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that using Oncotype DX (ODX)—the most commonly used test for predicting the benefit of adjuvant chemotherapy to reduce the risk of disease...

Oct 9th, 2018 - To update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer.

Oct 31st, 2017 - Patients with locally advanced invasive breast cancers are often treated with neoadjuvant chemotherapy prior to definitive surgical intervention. The primary aims of this approach are to: 1) reduce tumor burden thereby permitting breast conservati.

Oct 9th, 2014 - To identify optimal chemo- and targeted therapy for women with HER2 negative (or unknown) advanced breast cancer.

Dec 31st, 2008 - Dexrazoxane: not recommended for routine use in breast cancer (BC) in adjuvant setting, or metastatic setting with initial doxorubicin-based chemotherapy. Consider use with metastatic BC and other malignancies, for patients who have received >300.

Feb 11th, 2021 - Left-ventricular (LV) strain measurements with the Displacement Encoding with Stimulated Echoes (DENSE) MRI sequence provide accurate estimates of cardiotoxicity damage related to breast cancer chemotherapy. This study investigated an automated LV...

Jan 8th, 2021 - Different tumor-related factors have been proposed to assess the risk of disease progression and death in women undergoing neoadjuvant breast cancer chemotherapy. Recently, besides the classical pre-treatment clinical stage (CS) and post-treatment...

Aug 25th, 2020 - Multidrug resistance (MDR) limits the beneficial outcomes of conventional breast cancer chemotherapy. Ras-related nuclear protein (Ran-GTP) plays a key role in these resistance mechanisms, assisting cancer cells to repair damage to DNA. Herein, we...

Aug 4th, 2020 - Progress in oncology has allowed to improve outcomes in many breast cancer patients. The core stone of breast cancer chemotherapy is anthracycline-based chemotherapy. Unfortunately, anthracyclines cause cardiotoxicity which is a limiting factor of...

Jul 19th, 2020 - Our study aimed to analyze the risk of hematologic malignancies (HM) associated with the use of G-CSF with chemotherapy for BC. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident breast ca...

Jan 22nd, 2019 - New research in the January 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that using Oncotype DX (ODX)—the most commonly used test for predicting the benefit of adjuvant chemotherapy to reduce the risk of disease...

Jun 13th, 2018

Dec 22nd, 2015 - Ovarian suppression with triptorelin during chemotherapy for early-stage breast cancer significantly increased the chances that women would recover their long-term ovarian function, according to a multicenter phase III open-label study published o.

Apr 3rd, 2014 - Mariana Chavez-MacGregor, MD Breast cancer patients whose chemotherapy is initiated >60 days following surgery experience worse survival outcomes, according to a large, retrospective review of patient medical records conducted by Mariana Chavez-Ma...

Jun 2nd, 2013 - CHICAGO, Illinois — In a result that should change clinical practice, a low-dose weekly schedule of the breast cancer chemotherapy stalwart paclitaxel appears to be less toxic than the standard "dose-dense" biweekly administration of the drug, acc...